Hepatitis Prevention

;

House testimony on FY26 appropriations for HIV and hepatitis programs

Apr 9, 2025

This testimony is in support of funding for the following initiatives, programs and divisions at the Department of Health and Human Services: Ending the HIV Epidemic Initiative—$395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program—$3.024 billion; CDC Division of HIV Prevention—$822.7 million; CDC Division of Viral Hepatitis—$150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy—$20 million. The HIV+Hepatitis Policy Institute also supports maintaining and funding CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of School and Adolescent Health; the Minority HIV/AIDS Initiative; AIDS Research 2 at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA HIV Block Grant.

read more

Comments on updated HIV & hepatitis strategic plans

Dec 5, 2024

As a policy and advocacy organization we work to ensure there are the proper policies, programs, and funding to implement the Strategic Plans. We also refer to them in our work with the Congress, media, and the public to help educate them on the strategic plans and national goals included in each of the plans. We use them to measure our progress in meeting the goals. We not only use them to advocate before the Congress but also within government agencies and leadership to hold them accountable to ensure the goals are reached and that proper policies and programs are in place with sufficient funding.

read more

Testimony in support of increased funding for domestic HIV and hepatitis programs in the House FY 2023 Labor, HHS spending bill

May 24, 2022

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2023 Labor, HHS spending bill. Our nation is on a path to eliminating two infectious diseases, HIV and viral hepatitis, but we need increased funding to accelerate our efforts particularly in communities and populations disproportionately impacted. Increased investment in surveillance, education, prevention, and care and treatment will ensure we continue to address HIV and viral hepatitis, including taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both HIV and hepatitis.

read more

Testimony on FY 2023 appropriations for HIV and hepatitis programs

May 10, 2022

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2023 Labor, HHS spending bill. The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest